Ph. Eur. 5.1.13 Pyrogenic Risk Assessment & Dossiers

CellMade provides turnkey scientific and regulatory consultancy designed to fulfill the mandatory requirements of European Pharmacopoeia General Chapter 5.1.13 for replacing animal-based pyrogen testing. We help biopharmaceutical manufacturers transition from legacy methods by constructing defensible, risk-based contamination control strategies. By combining rigorous lifecycle risk mapping with empirical comparative batch data, we author complete CTD dossier packages and regulatory variations. Our end-to-end support ensures your non-endotoxin pyrogen (NEP) testing strategy meets EDQM and EMA expectations without introducing regulatory delays.

• Lifecycle Pyrogenic Risk Evaluation: Formalized, documented risk mapping across raw materials, cell substrates, bioprocess intermediates, and equipment contact surfaces to systematically identify potential Non-Endotoxin Pyrogen (NEP) exposure points.

• Comparative Testing & Method Justification: Empirical batch screening studies comparing Bacterial Endotoxin Testing (BET) alongside Monocyte Activation Testing (MAT) to scientifically justify whether BET alone or routine MAT lot release is required.

• CTD Dossier & Variation Authoring: Compilation of complete regulatory submission packages—including CTD Module 3 updates (3.2.P.5)—and Type IA/IB/II variation dossiers for seamless filing with the EMA and national health authorities.

• Change Control & Re-Validation Support: Audit-ready risk re-assessments, post-approval testing protocols, and documentation support for manufacturing process updates, scale-up, or raw material supplier changes.